Skip to main content
Thomas Walters, MD, Ophthalmology, Austin, TX, Ascension Seton Medical Center Austin

ThomasRichardWaltersMD

Ophthalmology Austin, TX

Cataract Related

Physician

Dr. Walters is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Walters' full profile

Already have an account?

Summary

  • Dr. Thomas Walters is an ophthalmologist in Austin, TX. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 35 years. He specializes in lens refractive surgery, cataract surgery, refractive laser surgery, and comprehensive ophthalmology.

Education & Training

  • Texas A&M College of Medicine-Scott and White Medical Center (Temple)
    Texas A&M College of Medicine-Scott and White Medical Center (Temple)Residency, Ophthalmology, 1983 - 1986
  • Texas A&M College of Medicine-Scott and White Medical Center (Temple)
    Texas A&M College of Medicine-Scott and White Medical Center (Temple)Internship, Internal Medicine, 1982 - 1983
  • University of Texas Southwestern Medical School
    University of Texas Southwestern Medical SchoolClass of 1982

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1983 - 2025
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Lifetime Achievement Award American Academy of Ophthalmology, 2020
  • Fellow (FAAO) American Academy of Ophthalmology
  • Super Doctor SuperDoctors.com
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019
    Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019May 6th, 2019
  • Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients with Glaucoma
    Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients with GlaucomaFebruary 3rd, 2017
  • iPad Screenings Effective for Detecting Early Signs of Glaucoma in Underserved, High-Risk Populations
    iPad Screenings Effective for Detecting Early Signs of Glaucoma in Underserved, High-Risk PopulationsOctober 19th, 2014

Professional Memberships

Hospital Affiliations